HLA-DRA Antikörper (AA 26-221)
Kurzübersicht für HLA-DRA Antikörper (AA 26-221) (ABIN7619260)
Target
Alle HLA-DRA Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 26-221
-
Verwendungszweck
- HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA) Polyclonal Antibody
-
Sequenz
- Ala26~Cys221
-
Produktmerkmale
- The HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA) Polyclonal Antibody (Species: Rabbit) has been validated for the following applications: WB, IHC.
-
Aufreinigung
- Antigen-specific affinity chromatography followed by Protein A affinity chromatography
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.5 mg/mL
-
Buffer
- 0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- 2°C to 8°C for frequent use, -20°C for 12 months. Avoid repeated freeze/thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- HLA-DRA (HLA Class II DR alpha (HLA-DRA))
-
Andere Bezeichnung
- HLA-DRA
-
Gen-ID
- 100328929
-
UniProt
- Q30847
-
Pathways
- T-Zell Rezeptor Signalweg, CXCR4-mediated Signaling Events, Human Leukocyte Antigen (HLA) in Adaptive Immune Response
Target
-